Gu, ZhenyangWang, LiYuan, LeiHuang, WenrongLi, MengGuan, LixunWang, QingyiGao, ZheZhao, ShashaLuo, LanWang, FeiyanYang, NanLiu, DaihongAster, JonGao, Chunji2017-12-052017Gu, Z., L. Wang, L. Yuan, W. Huang, M. Li, L. Guan, Q. Wang, et al. 2017. “Similar outcomes after haploidentical transplantation with post-transplant cyclophosphamide versus HLA-matched transplantation: a meta-analysis of case-control studies.” Oncotarget 8 (38): 63574-63586. doi:10.18632/oncotarget.18862. http://dx.doi.org/10.18632/oncotarget.18862.http://nrs.harvard.edu/urn-3:HUL.InstRepos:34491989Background: Outcomes of haploidentical hematopoietic cell transplantation (haplo-HCT) with post-transplant cyclophosphamide (PT-Cy) have greatly improved. It remains unknown whether haplo-HCT with PT-Cy was associated with poor outcomes when compared with HLA-matched HCT. To address this issue, we performed a meta-analysis to compare outcomes of haplo-HCT with PT-Cy with those of HLA-matched HCT. Methods: A systematic search for case-control studies were performed in PubMed, Embase and Cochrane Library databases. Using a random model, the risk ratios (RRs) and 95% confidence intervals (95% CI) were pooled for the final analysis. Results: Nine case-control studies including 2258 patients (827 patients in the haplo-HCT with PT-Cy group, 748 controls from HLA-matched related donors (MRD), and 683 controls from HLA-matched unrelated donors (MUD)) met the inclusion criteria. No differences were found between haplo-HCT with PT-Cy and HLA-matched HCT with regard to acute graft-versus-host-disease (GVHD), non-relapse mortality, relapse, progression free survival and overall survival. However, haplo-HCT with PT-Cy was found to be associated with a lower incidence of moderate to severe chronic GVHD (Haplo vs MRD: RR=0.54; 95% CI=0.39-0.75; Haplo vs MUD: RR=0.70; 95% CI=0.56-0.88). Conclusions: The results of this meta-analysis suggest that haplo-HCT with PT-Cy can achieve comparable outcomes with those of HLA-matched HCT. Haploidentical donors can be a feasible and valid alternative when conventional HLA-matched donors are unavailable.en-USpost-transplant cyclophosphamidehaploidenticalhematopoietic cell transplantationHLA-matchedsimilar outcomesJournal Article2017-12-0510.18632/oncotarget.18862